

## **Intezyne Sets Standard for Entrepreneurship and Creativity**

-- Company Receives the Governor's Business Diversification  
Entrepreneurship Award for the Mega Market Category --

**TAMPA, FL - September 15, 2009** — Intezyne today announced it has been honored with the Governor's Business Diversification Entrepreneurship Award. The Award is given annually to start-up companies that set the standard for entrepreneurship and creativity. The Entrepreneurship Award is one of six Governor's Business Diversification Awards which recognize Florida companies in emerging and high-technology industries for their contributions to the State's economic growth and diversity.

Since its inception in 2004, Intezyne has created a uniquely broad and powerful platform technology for encapsulating highly effective therapeutic compounds, as well as various diagnostic and imaging reagents. The Company's proprietary synthetic polymer technology is capable of delivering these agents safely and specifically to target tissues in the body. Intezyne has chosen to focus initially on oncology, due to the dose-limiting safety issues associated with most top-line chemotherapies and the ongoing need for highly targeted therapies in this category.

"We are very proud Intezyne is being honored with this prestigious state award," said Habib Skaff, Ph.D., Chief Executive Officer of Intezyne. "In these few short years, the Company has grown from four to eleven highly-skilled employees and, in addition to generating a patent-protected method of drug encapsulation known as the IVECT™ Method, the Company has developed two oncology products which soon will enter clinical trials. Intezyne's goal is to improve cancer therapy by developing a diverse arsenal of new drugs that are both safe *and* effective."

The Governor's Business Diversification Awards are sponsored by Enterprise Florida, Bank of America and *Florida Trend* Magazine and are designed to spotlight excellence

in Florida's business community. Companies established in 2004 or later may be eligible for the 2009 Governor's Entrepreneurship Award. Nominees are compared against companies from counties of similar population size, and evaluated based on their contributions to Florida's job growth and corporate citizenship, projected revenues and strategies, and their ability to offer distinctive products/services, develop sound business goals and overcome the challenges associated with starting a new business. Intezyne represents Hillsborough County in the Mega Market category. The Mega Market category includes Florida counties with a population of 800,001 and higher.

The Governor's Business Diversification Awards will be presented by Florida's Governor Charlie Crist at the Governor's Award Luncheon on September 15, 2009, as part of the State of Florida's 26th Annual Industry Appreciation Week.

### **About Intezyne**

Intezyne is dedicated to treating cancer better by offering a new solution to oncologists, who must balance the anti-tumor activity of best-in-class chemotherapeutics with their severe toxicities. Drawing from their expertise in polymer chemistry, the Company's founders created the IVECT Method to limit chemotherapeutics' anti-tumor activity to within the tumor itself, thereby sparing healthy tissues. To date, the IVECT Method has shown positive preclinical efficacy and safety profiles in multiple cancer models versus best-in-class chemotherapeutic agents, and the Company expects to file its first IND in early 2010. Ultimately, the IVECT Method has demonstrated preclinical proof-of-concept in a number of therapeutic and diagnostic categories, giving the Company the opportunity to monetize this asset through licensing agreements outside of Intezyne's primary oncology focus.

### **About the IVECT Method**

Intezyne's IVECT Method is a unique and remarkably safe platform that has the potential to raise the bar in terms of what patients and oncologists can expect from chemotherapy. The key to this breakthrough technology is the Company's multi-disciplinary approach, integrating polymer physics and materials science with organic

chemistry, polymer chemistry, biochemistry, and biology. Intezyne can improve patient outcomes significantly by amplifying the efficacy and safety profiles of best-in-class cancer drugs, whose potency often is handicapped by nonspecific delivery outside of the tumor site, requiring higher dosing and resulting in severe toxicities. The IVECT Method has proven to be extraordinarily versatile, in terms of the diversity of materials that can be encapsulated securely, and its unique modular design confers unmatched adaptability at a minimal cost. Beyond chemotherapy, the Company has proven the IVECT Method can deliver many classes of small molecules, in addition to nucleic acids, oligopeptides, and diagnostic imaging agents.

# # #

For more information, please visit [www.intezyne.com](http://www.intezyne.com), or contact:

Habib Skaff  
Intezyne  
(813) 910-2120  
[habib.skaff@intezyne.com](mailto:habib.skaff@intezyne.com)

For Investors:  
Juliane Snowden  
Burns McClellan  
(212) 213-0006  
[jsnowden@burnsmc.com](mailto:jsnowden@burnsmc.com)

For Media:  
Justin Jackson  
Burns McClellan  
(212) 213-0006  
[jjackson@burnsmc.com](mailto:jjackson@burnsmc.com)